PMID- 27615008
OWN - NLM
STAT- MEDLINE
DCOM- 20171103
LR  - 20221207
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 54
IP  - 12
DP  - 2016 Dec
TI  - Predictors of response to ipragliflozin treatment in patients with type 2 
      diabetes mellitus.
PG  - 1004-1008
AB  - OBJECTIVE: The aim of the present study was to investigate the efficacy and 
      safety of ipragliflozin treatment on glycemic control in patients with type 2 
      diabetes mellitus (T2DM). METHODS: We recruited 44 patients with T2DM, treated 
      them with 50 mg/day of ipragliflozin for 12 weeks, and assessed several diabetic 
      variables before and after treatment. We used stepwise multiple regression 
      analysis to evaluate response to ipragliflozin in terms of changes in hemoglobin 
      A1c (HbA1c) levels after therapy. RESULTS: Treatment with ipragliflozin for 12 
      weeks significantly decreased fasting glucose, HbA1c, and blood pressure levels 
      without severe adverse events. The baseline HbA1c (beta = -0.52, p < 0.01) and 
      alanine aminotransferase (ALT) levels (beta = -0.29, p = 0.03) were independently 
      and significantly related to a decrease in HbA1c levels. CONCLUSIONS: In patients 
      with T2DM, ipragliflozin treatment improved glycemic control, and baseline HbA1c 
      and ALT levels appeared to predict treatment response.
FAU - Okada, Kenta
AU  - Okada K
FAU - Kotani, Kazuhiko
AU  - Kotani K
FAU - Ebihara, Ken
AU  - Ebihara K
FAU - Yamazaki, Hisataka
AU  - Yamazaki H
FAU - Ishibashi, Shun
AU  - Ishibashi S
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 3N2N8OOR7X (ipragliflozin)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - Aged
MH  - Alanine Transaminase
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glucosides/*therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Thiophenes/*therapeutic use
EDAT- 2016/09/13 06:00
MHDA- 2017/11/04 06:00
CRDT- 2016/09/13 06:00
PHST- 2016/11/18 00:00 [accepted]
PHST- 2016/09/13 06:00 [pubmed]
PHST- 2017/11/04 06:00 [medline]
PHST- 2016/09/13 06:00 [entrez]
AID - 14718 [pii]
AID - 10.5414/CP202622 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2016 Dec;54(12):1004-1008. doi: 10.5414/CP202622.